Literature DB >> 30522135

Migraine and Tension-Type Headache.

Azmin Kahriman1, Shuhan Zhu1.   

Abstract

Migraine and tension-type headache (TTH) are common primary disorders that carry significant morbidity and socioeconomic effect. In this article, we will review the epidemiology, presentation, and diagnosis of these disorders. First-line acute treatment for migraine consists of analgesics, triptans, and antiemetics, while nonsteroidal anti-inflammatory drugs are the mainstay treatment for TTH. Patients with frequent or chronic headaches warrant prophylactic therapy. For migraine, various classes of preventives can be used (β-blockers, tricyclics, antiepileptics, botulinum toxin), with the choice of therapy tailored to the patient's risk factors and symptoms. For TTH, tricyclics have the most evidence as prophylactic therapy. A new class of medication, monoclonal antibodies to calcitonin gene receptor peptide or its receptor, became available in 2018, and is the first class of medication specifically designed to treat migraine. In addition to pharmacotherapy, we will also review nonpharmacologic interventions as well as neuromodulation for migraine. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30522135     DOI: 10.1055/s-0038-1673683

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  6 in total

Review 1.  Co-occurrence of pain syndromes.

Authors:  Giannapia Affaitati; Raffaele Costantini; Claudio Tana; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Neural Transm (Vienna)       Date:  2019-11-29       Impact factor: 3.575

2.  Factors Affecting Preventive Treatment Outcomes for Patients With Newly Diagnosed Chronic Migraine and Their Compliance With Treatment Recommendations in Chongqing Province, China: An Open-Label Prospective Study With Retrospective Baseline.

Authors:  Dongli Yuan; Yixin Zhang; Qin Li; Yuhua Lv; Xuelian Li; Yichuan Yu; Wangwen Li; Ge Tan
Journal:  Front Neurol       Date:  2020-04-09       Impact factor: 4.003

3.  Network Pharmacology and Metabolomics Studies on Antimigraine Mechanisms of Da Chuan Xiong Fang (DCXF).

Authors:  Shiyu Ma; Lin Zheng; Xiao Lin; Yi Feng; Ming Yang; Lan Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-20       Impact factor: 2.629

4.  Complementary and alternative therapies for tension-type headache: A protocol for systematic review and network meta-analysis.

Authors:  Xixi Zhai; Sishuo Zhang; Chuancheng Li; Fei Liu; Qing Huo
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 5.  Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches.

Authors:  Katarzyna Kępczyńska; Izabela Domitrz
Journal:  Toxins (Basel)       Date:  2022-09-05       Impact factor: 5.075

6.  Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use.

Authors:  Ricardo Ortiz; Lisa Gfrerer; Paul Panzenbeck; Marek A Hansdorfer; William G Austen
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.